Quality of life with pharmacological treatment in patients with benign prostatic enlargement: Results from the evolution European prospective multicenter multi-national registry study
BAUS ePoster online library. Bhatt N. 11/10/20; 304119; P8-1 Disclosure(s): Financial disclosure: The Evolution registry was supported by a restricted Grant from GlaxoSmithKline© (GSK).
Ms. Nikita Bhatt
Ms. Nikita Bhatt
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)
Quality of life with pharmacological treatment in patients with benign prostatic enlargement: Results from the evolution European prospective multicenter multi-national registry study

Bhatt N1, Davis N2, Witjes W3, Bjartell A4, Caris C3, Patel A5, de la Taille A6, Tubaro A7
1Queen Elizabeth Hospital, King's Lynn, United Kingdom, 2Beaumont Hospital, Dublin, Ireland, 3EAU Research Foundation, Arnhem, Netherlands, 4Lund University, Skane Hospital, Malmö, Sweden, 5Spire London East Hospital, United Kingdom, 6Assistance Publique des Hopitaux de Paris, Créteil, France, 7Sant'Andrea Hospital, Rome, Italy

Background:
The aim of this study was to evaluate the effect of pharmacological treatment of lower urinary tract symptoms due to benign prostate enlargement (LUTS/BPE) on disease- specific and generic Quality of Life (QOL) measures.

Methods:
Evolution was a European prospective, multicenter multi-national, observational registry collecting real life clinical data over two years on the management of LUTS/BPE in primary and secondary care. Disease-specific QOL using questionnaires like IPSS Q8, BPH Impact Index (BII) and generic QOL using questionnaires like EuroQOL Five Dimension (EQ5D) which encompassed EQ5D VAS and EQ5D health index were investigated.

Results:
The registry enrolled 1838 BPE patients and 1246 patients were evaluable at the end of 24 months. Nearly 70% of patients in the study were previously treated with medical therapy and 17% of these had already discontinued medical treatment previously for various reasons with lack of efficacy being the most common. The mean time since diagnosis of LUTS in the previously treated group was 4.7 years (0-26 years). Medical management produced statistically significant improvement in QOL (disease specific and generic) in patients previously untreated with medical therapy, and an insignificant change in generic QOL in those previously treated with medical treatment.

Conclusions:
After 5-years from the onset of symptoms, LUTS/BPE patients previously treated with medication had significantly impaired QOL in patients in a manner comparable to other chronic diseases. Earlier intervention with minimally invasive surgical techniques should be considered in LUTS/BPE patients that do not show a significant improvement in QOL with medical therapy.
Quality of life with pharmacological treatment in patients with benign prostatic enlargement: Results from the evolution European prospective multicenter multi-national registry study

Bhatt N1, Davis N2, Witjes W3, Bjartell A4, Caris C3, Patel A5, de la Taille A6, Tubaro A7
1Queen Elizabeth Hospital, King's Lynn, United Kingdom, 2Beaumont Hospital, Dublin, Ireland, 3EAU Research Foundation, Arnhem, Netherlands, 4Lund University, Skane Hospital, Malmö, Sweden, 5Spire London East Hospital, United Kingdom, 6Assistance Publique des Hopitaux de Paris, Créteil, France, 7Sant'Andrea Hospital, Rome, Italy

Background:
The aim of this study was to evaluate the effect of pharmacological treatment of lower urinary tract symptoms due to benign prostate enlargement (LUTS/BPE) on disease- specific and generic Quality of Life (QOL) measures.

Methods:
Evolution was a European prospective, multicenter multi-national, observational registry collecting real life clinical data over two years on the management of LUTS/BPE in primary and secondary care. Disease-specific QOL using questionnaires like IPSS Q8, BPH Impact Index (BII) and generic QOL using questionnaires like EuroQOL Five Dimension (EQ5D) which encompassed EQ5D VAS and EQ5D health index were investigated.

Results:
The registry enrolled 1838 BPE patients and 1246 patients were evaluable at the end of 24 months. Nearly 70% of patients in the study were previously treated with medical therapy and 17% of these had already discontinued medical treatment previously for various reasons with lack of efficacy being the most common. The mean time since diagnosis of LUTS in the previously treated group was 4.7 years (0-26 years). Medical management produced statistically significant improvement in QOL (disease specific and generic) in patients previously untreated with medical therapy, and an insignificant change in generic QOL in those previously treated with medical treatment.

Conclusions:
After 5-years from the onset of symptoms, LUTS/BPE patients previously treated with medication had significantly impaired QOL in patients in a manner comparable to other chronic diseases. Earlier intervention with minimally invasive surgical techniques should be considered in LUTS/BPE patients that do not show a significant improvement in QOL with medical therapy.
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies